Product Data Sheet

Product Name: Brentuximab vedotin
Cat. No.: GC68296

Chemical Properties

Cas. No.	914088-09-8	
Formula	M.Wt	
Solubility	Storage	-80°C,protect from light
General tips	For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.	
Shipping Condition	Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.	
Structure	Brentuximab vedotin	

Background

IC50: 2.5 ng/mL (CD30)[2]

Brentuximab vedotin (cAC10-vcMMAE) is an antibody-drug conjugate **(ADC)** comprising an anti-**CD30** antibody and the cytotoxic agent Monomethyl auristatin E (MMAE). Brentuximab vedotin inhibits **CD30**-positive cells with an $\mathbf{IC_{50}}$ of 2.5 ng/mL.
Brentuximab vedotin can be used for the research of relapsed and refractory Hodgkin lymphoma[1][2].

Brentuximab vedotin (cAC10-vcMMAE) (1 μg/mL; 96 h) shows cytotoxicity to $CD30^+$ in Karpas 299 cells[2].
Brentuximab vedotin (CAC10-VCMMAE) (1 μg/mL; 12, 24 and 48 h) selectively induces growth arrest in G2/M phase then lead to apoptotic cell death[2].

Cell Cytotoxicity Assay[2]

Cell Line:	Karpas 299 cells

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com
Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

Concentration:	1 μg/mL
Incubation Time:	96 h
Result:	Showed cytotoxicity to $CD30^+$ Karpas 299 cells with an IC_{50} value of 2.5 ng/mL.

Cell Cycle Analysis[2]

Cell Line:	L540 cells
Concentration:	1 μg/mL
Incubation Time:	12, 24, and 48 h
Result:	Selectively induced growth arrest in G2/M phase to apoptotic cell death.

Brentuximab vedotin (cAC10-vcMMAE) (10-120 mg/kg; i.p. for 3 weeks) the maximum tolerated dose (MTD) is between 30 and 40 mg/kg[2].
Brentuximab vedotin (cAC10-vcMMAE) (0.3, 1 mg/kg; flanks injection; every 4 days for a total of 4 doses 1 mg/kg) induces tumor CD30 regression[2].

Animal Model:	SCID mice[2]
Dosage:	10 to 120 mg/kg
Administration:	Intravenous injection; 10 to 120 mg/kg; for 3 weeks
Result:	Showed an maximum tolerated dose between 30 and 40 mg/kg.

Animal Model:	SCID mice[2]
Dosage:	0.3 and 1 mg/kg

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com
Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

Administration:	Flanks injection; 1 mg/kg every 4 days for a total of 4 doses; 0.3 mg/kg every 4 days for a total of 4 doses
Result:	Induced complete and durable tumor regression, but 0.3 mg/kg provided lower therapy than 1 mg/kg dose.

[1]. Shea L, Mehta-Shah N. Brentuximab Vedotin in the Treatment of Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma. Curr Hematol Malig Rep. 2020 Feb;15(1):9-19.
[2]. Francisco JA, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003 Aug 15;102(4):1458-65.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com
Address: 10292 Central Ave. #205, Montclair, CA, USA